Chinese biotech startup LongBio Pharma, a Qiming Venture Partners portfolio company, lists on the Hong Kong Stock Exchange. Qiming led LongBio Pharma’s B2 round in 2024 and co-led its C round in 2025; its pre-IPO stake was 4.27% before LongBio’s Hong Kong listing.
LongBio Pharma, a Qiming Venture Partners portfolio company developing innovative drugs for allergic and autoimmune diseases, lists on the Hong Kong Stock Exchange on June 5, 2026, Beijing time. The company (01779.HK) issues shares at HK$6.06 each and opens at HK$44.30, with a market capitalization of HK$0.7 billion; the listing marks Qiming Venture Partners’ seventh IPO of the year.
Chinese biotech Longbio Pharma announces an HKEX IPO to raise HK$1.362 billion (US$174 million) for its immunology programs. Proceeds are intended to advance LP-003, a next-generation anti-IgE antibody, and its broader immunology pipeline; the company files under Chapter 18A as a pre-revenue biotech.
LongBio reports positive topline results from a Phase II head-to-head trial of its next-generation anti-IgE therapy LP-003 against Xolair (omalizumab) in CSU. LP-003 demonstrates statistically superior outcomes in key efficacy endpoints, and the results are presented as a late-breaking poster at 2026 AAAAI.
